Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
Medaffcon expands its network of companies to Omicron ApS and Value Coaching Oy to extend the services available to pharmaceutical and MedTech companies.
Omicron is a Danish company specialized in biostatistics, statistical programming, and real-world evidence (RWE). The combined expertise of Omicron and Medaffcon represents the fields of RWE and data sciences. This collaboration provides the means to conduct real-world studies in an agile and tailored way across Finland and Denmark.
Value Coaching offers services in leadership consulting, coaching, and innovative workshops with strong experience in the pharmaceutical and MedTech industries. Collaboration with Value Coaching strengthens Medaffcon’s network’s service offering and enables conducting joint projects with broad scope and range of expertise.
These collaborations complement Medaffcon’s partner network and further strengthen our capabilities to provide Nordic-wide services.
Jarmo Hahl
Managing Director
tel: +358 40 139 4001
jarmo.hahl@medaffcon.com
Medaffcon Oy
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
The data team keeps Medaffcon's research projects on track and ensures that the research findings are scientifically sound. At the heart of the team’s work is the processing and analysis of patient data, particularly in Real-World Evidence (RWE) studies.
Medaffcon's European Lung Cancer Congress (ELCC) poster showcased key findings from a recent study on non-small cell lung cancer (NSCLC).